DOCSLIB.ORG

Monoclonal Antibodies Directed Against Cadherin RGD Exhibit Therapeutic Activity Against Melanoma and Colorectal Cancer Metastasis Ruben A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Monoclonal Antibodies Directed Against Cadherin RGD Exhibit Therapeutic Activity Against Melanoma and Colorectal Cancer Metastasis Ruben� A Published OnlineFirst September 15, 2017; DOI: 10.1158/1078-0432.CCR-17-1444 Biology of Human Tumors Clinical Cancer Research Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis Ruben A. Bartolome1, Carmen Aizpurua2, Marta Jaen 1, Sofía Torres1, Eva Calvino~ 1, Juan I. Imbaud2, and J. Ignacio Casal1 Abstract Purpose: New targets are required for the control of advanced vascular-endothelial (VE)-cadherin–mediated b1 integrin activa- metastatic disease. We investigated the use of cadherin RGD tion in melanoma and breast, pancreatic, and colorectal cancer motifs, which activate the a2b1integrin pathway, as targets for cells. Antibodies provoked a significant reduction in cell adhesion the development of therapeutic monoclonal antibodies (mAb). and proliferation of metastatic cancer cells. Treatment with mAbs Experimental Design: Cadherin 17 (CDH17) fragments and impaired the integrin signaling pathway activation of FAK in peptides were prepared and used for immunization and antibody colorectal cancer, of JNK and ERK kinases in colorectal and development. Antibodies were tested for inhibition of b1integrin pancreatic cancers, and of JNK, ERK, Src, and AKT in melanoma and cell adhesion, proliferation, and invasion assays using cell and breast cancer. In vivo, RGD-specific mAbs increased mouse lines from different cancer types (colorectal, pancreatic, melanoma, survival after inoculation of melanoma and colorectal cancer cell and breast cancer). Effects of the mAbs on cell signaling were lines to cause lung and liver metastasis, respectively. determined by Western blot analysis. Nude mice were used for Conclusions: Blocking the interaction between RGD cadher- survival analysis after treatment with RGD-specificmAbsandmetas- ins and a2b1 integrin with highly selective mAbs constitutes a tasis development. promising therapy against advanced metastatic disease in colon Results: Antibodies against full-length CDH17 failed to block cancer, melanoma, and, potentially, other cancers. Clin Cancer the binding to a2b1 integrin. However, CDH17 RGD peptides Res; 24(2); 1–12. Ó2017 AACR. generated highly selective RGD mAbs that blocked CDH17 and See related commentary by Marshall, p. 253 Introduction In colon cancer, CDH17 is expressed at low levels in primary tumors or in regional lymph node metastases, as well as in There is a necessity to find new therapeutic targets to control poorly differentiated colon cancer tumors (7). However, metastatic spread in cancer. Therapeutic monoclonal antibo- CDH17 is overexpressed in advanced colorectal cancer liver dies (mAb) against EGFR or VEGF(R) are in clinical use for the metastasis (8), where it correlates with poor prognosis (9). It treatment of advanced metastatic colorectal cancer. However, is also highly expressed in gastric cancer, esophagus carcinoma, their impact on the final outcome of patients with metastasis is pancreatic cancer (10), and hepatocarcinoma (11). CDH17 still limited (1), probably due to the difficulty of assessing the facilitates liver colonization and metastasis in orthotopic mouse EGFR status of the patients (2, 3), adverse effects related to the colorectal cancer models after intrasplenic injection (9, 12). wide distribution of these molecules in healthy tissues, and the CDH17 binds a2b1 integrin through an RGD motif and induces lack of response in patients with KRAS mutations (4). b1 integrin activation, which leads to increased cell adhesion to Cadherin 17 (CDH17), also known as liver–intestine (LI)- Matrigel and type IV collagen, and increased proliferation (12). cadherin, is present in fetal liver and the gastrointestinal tract, The CDH17 RAD mutant does not induce integrin signaling but exhibiting elevated expression during embryogenesis (5). rather leads to a reduction in tumor growth and liver coloni- CDH17 localizes to the basolateral domain of hepatocytes and þ zation (12). In colorectal cancer metastatic cells, we have enterocytes, where it mediates intercellular adhesion in a Ca(2 )- described a nonconventional situation in which a2b1 integrin dependent manner to maintain tissue integrity in epithelia (6). binds to cadherins in a RGD-dependent manner, making it conformationally activatable and allowing it to bind to type IV collagen. This finding modifies the classical notion that a2b1 1 Department of Cellular and Molecular Medicine, Centro de Investigaciones integrin binds type I collagen using the GFOGER motifs in a 2 Biologicas, CSIC, Madrid, Spain. Protein Alternatives SL, Tres Cantos, Madrid, RGD- and conformation-independent way (13, 14). Previous Spain. data support a preferential trans activation model for cadherin/ Note: Supplementary data for this article are available at Clinical Cancer integrin interaction, although cis interaction cannot be ruled out Research Online (http://clincancerres.aacrjournals.org/). (12). No activation effects were observed for the RGD motif on Corresponding Author: J. Ignacio Casal, Centro de Investigaciones Biologicas avora6b4 integrins. (CIB-CSIC), Ramiro de Maeztu 9, Madrid 28040, Spain. Phone: 34 918373112; Fax: RGD motifs are also present in vascular-endothelial (VE)- 34 915360432; E-mail: [email protected] cadherin, CDH6 [fetal kidney (K)-cadherin], and CDH20. doi: 10.1158/1078-0432.CCR-17-1444 VE-cadherin is expressed in aggressive human melanoma cell Ó2017 American Association for Cancer Research. lines and cutaneous melanomas (15), but not in poorly www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2017 American Association for Cancer Research. Published OnlineFirst September 15, 2017; DOI: 10.1158/1078-0432.CCR-17-1444 Bartolome et al. from Dr. A Villalobos (IIB-CSIC Madrid, Spain). RKO, Colo320, Translational Relevance and HT29 human colon cancer cells; A375 human melanoma Many unsuccessful attempts have been made in the last cells; and the pancreatic cancer cell line PANC1 were purchased decades to target integrins with RGD peptides for cancer from the ATCC and passaged for all of the experiments fewer therapy. Here, we have demonstrated that cellular cadherin than 6 months after purchase. BLM, SKBR3, and MDA-MB-468 RGD motifs are equally efficient and more selective targets for were not authenticated in our laboratory. All cell lines were integrin inhibition in metastatic cells than RGD peptides from tested regularly for Mycoplasma contamination and cultured in the extracellular matrix proteins. We describe the development DMEM (Invitrogen) containing 10% FCS (Invitrogen) and anti- fi and functional characterization of cadherin RGD-speci c biotics at 37 C in a 5% CO2 humidified atmosphere. monoclonal antibodies that have demonstrated an extraordi- CDH17 polyclonal antibodies (H-167 and C-17), RhoGDIa nary efficiency in blocking b1 integrin activation and protect- (G-2), VE-cadherin (BV9), and FAK (A-17) were purchased ing mice against liver and lung metastasis from colorectal from Santa Cruz Biotechnology. CDH17 antibody (#141713) cancer and melanoma, respectively. Our data support that and Src (AF3389) were from R&D Systems. Blocking anti-b1 these highly promising results also can be extended to breast, (P5D2), a4(ALC1/1),anda5 (P1D6) integrin antibodies were pancreatic, and other tumors. In summary, these highly selec- from Abcam. b1 integrin antibody specificforhigh-affinity tive monoclonal antibodies open a new avenue for the treat- conformation (HUTS-21) and pY397-FAK (#611722) were ment of metastasis in different types of cancer. from BD Transduction Laboratories. Antibodies against phos- pho-Src (#2101), JNK (56G8), phospho-JNK (G9), ERK1/2 (L24F12), and phospho-ERK1/2 (#9101) were from Cell Sig- naling Technology. Anti-a3 integrin (AB1920) was from EMD a aggressive cell lines isolated from the same tumors (16). VE- Millipore. The antibody against 1 (TS 2/7) integrin was a kind cadherin has been involved in vasculogenic mimicry (the gift from Dr. C. Bernabeu (CIB-CSIC). ability to form novel blood vessel–like structures) in uveal CDH17-derived peptides (VSLRGDTRG, SLRGDTR, and melanomas (16). It is also expressed in Ewing sarcoma (17) LRGDT), VE-cadherin domain 2 (QGLRGDSGT), VE-cadherin and promotes breast cancer progression (18). Recently, we domain 3 (SILRGDYQD), CDH6 (DQDRGDGSL), CDH16 have demonstrated that knocking down VE-cadherin sup- (RAIRGDTEG), and CDH20 (DMDRGDGSI) peptides were syn- presses the lung colonization capacity of melanoma or breast thesized using solid phase chemistry with a Focus XC instrument cancer cells inoculated in mice, whereas preincubation with (AAPPTec). In the CDH17 9-mer VSLRGDTRG, Tyr at position VE-cadherin RGD peptides promotes lung metastasis for both 600 was replaced with a Val to facilitate synthesis and hydrophi- cancer types (19). Like CDH17 RGD peptides, VE-cadherin licity. The cyclic RGD peptide Cilengitide was from Selleck RGD peptides cause b1 integrin activation, suggesting that the Chemicals. a a mechanisms of action for both cadherins are similar (12). siRNAs against human 1 (SASI_Hs01_00067020), 3 a We hypothesized that blocking the cadherin RGD motifs (SASI_Hs01_00196571), and 2 integrin (19) subunits were would provoke an inhibition of liver and lung metastasis purchased form Sigma-Aldrich and transfected using jetPRIME through a2b1 integrin inhibition. Here, we investigated the reagent (Polyplus Transfection). use of 9-mer peptides containing the CDH17 RGD motif and Immunization and preparation of mouse mAbs their flanking sequences
Load more

Recommended publications
  • Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for KN406551 Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) Product data: Product Type: Knockout Kits (CRISPR) Symbol: Cadherin 16 Locus ID: 1014 Kit Components: , 10 ug , 10 ug : EF1a-GFP-P2A-Puro Disclaimer: The kit is designed based on the best knowledge of CRISPR technology. The system has been functionally validated for knocking-in the cassette downstream the native promoter. The efficiency of the knock-out varies due to the nature of the biology and the complexity of the experimental process. RefSeq: NM_001204744, NM_001204745, NM_001204746, NM_004062 Summary: This gene is a member of the cadherin superfamily, genes encoding calcium-dependent, membrane-associated glycoproteins. Mapped to a previously identified cluster of cadherin genes on chromosome 16q22.1, the gene localizes with superfamily members CDH1, CDH3, CDH5, CDH8 and CDH11. The protein consists of an extracellular domain containing 6 cadherin domains, a transmembrane region and a truncated cytoplasmic domain but lacks the prosequence and tripeptide HAV adhesion recognition sequence typical of most classical cadherins. Expression is exclusively in kidney, where the protein functions as the principal mediator of homotypic cellular recognition, playing a role in the morphogenic direction of tissue development. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Mar 2011] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2020 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Cadherin 16 (CDH16) Human Gene Knockout Kit (CRISPR) – KN406551 Product images: This product is to be used for laboratory only.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Learning from Cadherin Structures and Sequences: Affinity Determinants and Protein Architecture
    Learning from cadherin structures and sequences: affinity determinants and protein architecture Klára Fels ıvályi Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Klara Felsovalyi All rights reserved ABSTRACT Learning from cadherin structures and sequences: affinity determinants and protein architecture Klara Felsovalyi Cadherins are a family of cell-surface proteins mediating adhesion that are important in development and maintenance of tissues. The family is defined by the repeating cadherin domain (EC) in their extracellular region, but they are diverse in terms of protein size, architecture and cellular function. The best-understood subfamily is the type I classical cadherins, which are found in vertebrates and have five EC domains. Among the five different type I classical cadherins, the binding interactions are highly specific in their homo- and heterophilic binding affinities, though their sequences are very similar. As previously shown, E- and N-cadherins, two prototypic members of the subfamily, differ in their homophilic K D by about an order of magnitude, while their heterophilic affinity is intermediate. To examine the source of the binding affinity differences among type I cadherins, we used crystal structures, analytical ultracentrifugation (AUC), surface plasmon resonance (SPR), and electron paramagnetic resonance (EPR) studies. Phylogenetic analysis and binding affinity behavior show that the type I cadherins can be further divided into two subgroups, with E- and N-cadherin representing each. In addition to the affinity differences in their wild-type binding through the strand-swapped interface, a second interface also shows an affinity difference between E- and N-cadherin.
    [Show full text]
  • Somatic Mutational Landscapes of Adherens Junctions and Their
    1 Somatic mutational landscapes of adherens junctions and their 2 functional consequences in cutaneous melanoma development 3 4 Praveen Kumar Korla,1 Chih-Chieh Chen,2 Daniel Esguerra Gracilla,1 Ming-Tsung Lai,3 Chih- 5 Mei Chen,4 Huan Yuan Chen,5 Tritium Hwang,1 Shih-Yin Chen,4,6,* Jim Jinn-Chyuan Sheu1,4, 6-9,* 6 1Institute of Biomedical Sciences, National Sun Yat-sen University, Kaohsiung 80242, Taiwan; 7 2Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung 80424, 8 Taiwan; 3Department of Pathology, Taichung Hospital, Ministry of Health and Welfare, Taichung 9 40343, Taiwan; 4Genetics Center, China Medical University Hospital, Taichung 40447, Taiwan; 10 5Institute of Biomedical Sciences, Academia Sinica, Taipei 11574, Taiwan; 6School of Chinese 11 Medicine, China Medical University, Taichung 40402, Taiwan; 7Department of Health and 12 Nutrition Biotechnology, Asia University, Taichung 41354, Taiwan; 8Department of 13 Biotechnology, Kaohsiung Medical University, Kaohsiung 80708, Taiwan; 9Institute of 14 Biopharmaceutical Sciences, National Sun Yat-sen University, Kaohsiung 80242, Taiwan 15 16 PKK, CCC and DEG contributed equally to this study. 17 *Correspondence to: Dr. Shih-Yin Chen ([email protected]) at Genetics Center, China 18 Medical University Hospital, Taichung, 40447, TAIWAN; or Dr. Jim Jinn-Chyuan Sheu 19 ([email protected]) at Institute of Biomedical Sciences, National Sun Yat-sen 20 University, Kaohsiung City 80424, TAIWAN. 21 22 Running title: mutational landscape of cadherins in melanoma 1 23 Abstract 24 Cell-cell interaction in skin homeostasis is tightly controlled by adherens junctions (AJs). 25 Alterations in such regulation lead to melanoma development.
    [Show full text]
  • MALE Protein Name Accession Number Molecular Weight CP1 CP2 H1 H2 PDAC1 PDAC2 CP Mean H Mean PDAC Mean T-Test PDAC Vs. H T-Test
    MALE t-test t-test Accession Molecular H PDAC PDAC vs. PDAC vs. Protein Name Number Weight CP1 CP2 H1 H2 PDAC1 PDAC2 CP Mean Mean Mean H CP PDAC/H PDAC/CP - 22 kDa protein IPI00219910 22 kDa 7 5 4 8 1 0 6 6 1 0.1126 0.0456 0.1 0.1 - Cold agglutinin FS-1 L-chain (Fragment) IPI00827773 12 kDa 32 39 34 26 53 57 36 30 55 0.0309 0.0388 1.8 1.5 - HRV Fab 027-VL (Fragment) IPI00827643 12 kDa 4 6 0 0 0 0 5 0 0 - 0.0574 - 0.0 - REV25-2 (Fragment) IPI00816794 15 kDa 8 12 5 7 8 9 10 6 8 0.2225 0.3844 1.3 0.8 A1BG Alpha-1B-glycoprotein precursor IPI00022895 54 kDa 115 109 106 112 111 100 112 109 105 0.6497 0.4138 1.0 0.9 A2M Alpha-2-macroglobulin precursor IPI00478003 163 kDa 62 63 86 72 14 18 63 79 16 0.0120 0.0019 0.2 0.3 ABCB1 Multidrug resistance protein 1 IPI00027481 141 kDa 41 46 23 26 52 64 43 25 58 0.0355 0.1660 2.4 1.3 ABHD14B Isoform 1 of Abhydrolase domain-containing proteinIPI00063827 14B 22 kDa 19 15 19 17 15 9 17 18 12 0.2502 0.3306 0.7 0.7 ABP1 Isoform 1 of Amiloride-sensitive amine oxidase [copper-containing]IPI00020982 precursor85 kDa 1 5 8 8 0 0 3 8 0 0.0001 0.2445 0.0 0.0 ACAN aggrecan isoform 2 precursor IPI00027377 250 kDa 38 30 17 28 34 24 34 22 29 0.4877 0.5109 1.3 0.8 ACE Isoform Somatic-1 of Angiotensin-converting enzyme, somaticIPI00437751 isoform precursor150 kDa 48 34 67 56 28 38 41 61 33 0.0600 0.4301 0.5 0.8 ACE2 Isoform 1 of Angiotensin-converting enzyme 2 precursorIPI00465187 92 kDa 11 16 20 30 4 5 13 25 5 0.0557 0.0847 0.2 0.4 ACO1 Cytoplasmic aconitate hydratase IPI00008485 98 kDa 2 2 0 0 0 0 2 0 0 - 0.0081 - 0.0
    [Show full text]
  • And MUC1 in Mammary Epithelial Cells
    Linköping University Post Print Loss of ICAM-1 signaling induces psoriasin (S100A7) and MUC1 in mammary epithelial cells Stina Petersson, E. Shubbar, M. Yhr, A. Kovacs and Charlotta Enerbäck N.B.: When citing this work, cite the original article. The original publication is available at www.springerlink.com: Stina Petersson, E. Shubbar, M. Yhr, A. Kovacs and Charlotta Enerbäck, Loss of ICAM-1 signaling induces psoriasin (S100A7) and MUC1 in mammary epithelial cells, 2011, Breast Cancer Research and Treatment, (125), 1, 13-25. http://dx.doi.org/10.1007/s10549-010-0820-4 Copyright: Springer Science Business Media http://www.springerlink.com/ Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-63954 1 Loss of ICAM-1 signaling induces psoriasin (S100A7) and MUC1 in mammary epithelial cells Petersson S1, Shubbar E1, Yhr M1, Kovacs A2 and Enerbäck C3 Departments of 1Clinical Genetics and 2Pathology, Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden; 3Department of Clinical and Experimental Medicine, Division of Cell Biology and Dermatology, Linköping University, SE-581 85 Linköping, Sweden E-mail: [email protected] E-mail: maria.yhr@ clingen.gu.se E-mail: [email protected] E-mail: [email protected] Correspondence: Stina Petersson, Department of Clinical Genetics, Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden E-mail: [email protected] 2 Abstract Psoriasin (S100A7), a member of the S100 gene family, is highly expressed in high-grade comedo ductal carcinoma in situ (DCIS), with a higher risk of local recurrence. Psoriasin is therefore a potential biomarker for DCIS with a poor prognosis.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Minimal 16Q Genomic Loss Implicates Cadherin-11 in Retinoblastoma
    Minimal 16q Genomic Loss Implicates Cadherin-11 in Retinoblastoma Mellone N. Marchong,1,2 Danian Chen,1,6 Timothy W. Corson,1,3 Cheong Lee,1 Maria Harmandayan,1 Ella Bowles,1 Ning Chen,5 and Brenda L. Gallie1,2,3,4,5 1Divisions of Cancer Informatics and Cellular and Molecular Biology, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada; Departments of 2Medical Biophysics, 3Molecular and Medical Genetics, and 4Ophthalmology, University of Toronto, Toronto, Ontario, Canada; 5Retinoblastoma Solutions, Toronto, Ontario, Canada; and 6Department of Ophthalmology, West China Hospital, Faculty of Medicine, Sichuan University, Chengdu, People’s Republic of China Abstract compared with normal adult human retina. Our analyses Retinoblastoma is initiated by loss of both RB1 alleles. implicate CDH11, but not CDH13, as a potential tumor Previous studies have shown that retinoblastoma suppressor gene in retinoblastoma. (Mol Cancer Res tumors also show further genomic gains and losses. We 2004;2(9):495–503) now define a 2.62 Mbp minimal region of genomic loss of chromosome 16q22, which is likely to contain tumor suppressor gene(s), in 76 retinoblastoma tumors, using Introduction loss of heterozygosity (30 of 76 tumors) and quantitative Retinoblastoma is the most common intraocular tumor in multiplex PCR (71 of 76 tumors). The sequence-tagged children. Mutations of both alleles (M1 and M2) of the RB1 site WI-5835 within intron 2 of the cadherin-11 (CDH11) gene at chromosome 13q14 are necessary (1) for retinoblastoma gene showed the highest frequency of loss (54%, 22 of tumor initiation but not sufficient for malignant transformation 41 samples tested).
    [Show full text]
  • Supplementary Table 1: Differentially Methylated Genes and Functions of the Genes Before/After Treatment with A) Doxorubicin and B) FUMI and in C) Responders Vs
    Supplementary Table 1: Differentially methylated genes and functions of the genes before/after treatment with a) doxorubicin and b) FUMI and in c) responders vs. non- responders for doxorubicin and d) FUMI Differentially methylated genes before/after treatment a. Doxo GENE FUNCTION CCL5, CCL8, CCL15, CCL21, CCR1, CD33, IL5, immunoregulatory and inflammatory processes IL8, IL24, IL26, TNFSF11 CCNA1, CCND2, CDKN2A cell cycle regulators ESR1, FGF2, FGF14, FGF18 growth factors WT1, RASSF5, RASSF6 tumor suppressor b. FUMI GENE FUNCTION CCL7, CCL15, CD28, CD33, CD40, CD69, TNFSF18 immunoregulatory and inflammatory processes CCND2, CDKN2A cell cycle regulators IGF2BP1, IGFBP3 growth factors HOXB4, HOXB6, HOXC8 regulation of cell transcription WT1, RASSF6 tumor suppressor Differentially methylated genes in responders vs. non-responders c. Doxo GENE FUNCTION CBR1, CCL4, CCL8, CCR1, CCR7, CD1A, CD1B, immunoregulatory and inflammatory processes CD1D, CD1E, CD33, CD40, IL5, IL8, IL20, IL22, TLR4 CCNA1, CCND2, CDKN2A cell cycle regulators ESR2, ERBB3, FGF11, FGF12, FGF14, FGF17 growth factors WNT4, WNT16, WNT10A implicated in oncogenesis TNFSF12, TNFSF15 apoptosis FOXL1, FOXL2, FOSL1,HOXA2, HOXA7, HOXA11, HOXA13, HOXB4, HOXB6, HOXB8, HOXB9, HOXC8, regulation of cell transcription HOXD8, HOXD9, HOXD11 GSTP1, MGMT DNA repair APC, WT1 tumor suppressor d. FUMI GENE FUNCTION CCL1, CCL3, CCL5,CCL14, CD1B, CD33, CD40, CD69, immunoregulatory and inflammatory IL20, IL32 processes CCNA1, CCND2, CDKN2A cell cycle regulators IGF2BP1, IGFBP3, IGFBP7, EGFR, ESR2,RARB2
    [Show full text]
  • Supplementary Table 1
    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
    [Show full text]
  • Bioinformatics Analysis to Screen Key Genes in Papillary Thyroid Carcinoma
    ONCOLOGY LETTERS 19: 195-204, 2020 Bioinformatics analysis to screen key genes in papillary thyroid carcinoma YUANHU LIU1*, SHUWEI GAO2*, YAQIONG JIN2, YERAN YANG2, JUN TAI1, SHENGCAI WANG1, HUI YANG2, PING CHU2, SHUJING HAN2, JIE LU2, XIN NI1,2, YONGBO YU2 and YONGLI GUO2 1Department of Otolaryngology, Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; 2Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, MOE Key Laboratory of Major Diseases in Children, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, P.R. China Received April 22, 2019; Accepted September 24, 2019 DOI: 10.3892/ol.2019.11100 Abstract. Papillary thyroid carcinoma (PTC) is the most verifying their potential for clinical diagnosis. Taken together, common type of thyroid carcinoma, and its incidence has the findings of the present study suggest that these genes and been on the increase in recent years. However, the molecular related pathways are involved in key events of PTC progression mechanism of PTC is unclear and misdiagnosis remains a and facilitate the identification of prognostic biomarkers. major issue. Therefore, the present study aimed to investigate this mechanism, and to identify key prognostic biomarkers. Introduction Integrated analysis was used to explore differentially expressed genes (DEGs) between PTC and healthy thyroid tissue. To Thyroid carcinoma is the most common malignancy of investigate the functions and pathways associated with DEGs, the head and neck, and accounts for 91.5% of all endocrine Gene Ontology, pathway and protein-protein interaction (PPI) malignancies (1).
    [Show full text]